Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive

Serena Ferrari, Marianna Cannoletta, Matteo Generali, Lucia Cazzato, Angelo CagnacciDepartment of Obstetrics, Gynecology, and Pediatrics, Azienda Ospedaliero, Universitaria di Modena, ItalyAbstract: Since their introduction in 1959, development of hormonal contraceptives has been ongoing, with the u...

Full description

Bibliographic Details
Main Authors: Serena Ferrari, Marianna Cannoletta, Matteo Generali, et al.
Format: Article
Language:English
Published: Dove Medical Press 2010-09-01
Series:Open Access Journal of Contraception
Online Access:http://www.dovepress.com/efficacy-safety-and-patient-acceptability-of-the-combined-chlormadinon-a5199
id doaj-63acb38e68f044a3be7275e69e83ea0f
record_format Article
spelling doaj-63acb38e68f044a3be7275e69e83ea0f2020-11-24T23:21:51ZengDove Medical PressOpen Access Journal of Contraception1179-15272010-09-012010default93101Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptiveSerena FerrariMarianna Cannoletta, Matteo Generaliet al.Serena Ferrari, Marianna Cannoletta, Matteo Generali, Lucia Cazzato, Angelo CagnacciDepartment of Obstetrics, Gynecology, and Pediatrics, Azienda Ospedaliero, Universitaria di Modena, ItalyAbstract: Since their introduction in 1959, development of hormonal contraceptives has been ongoing, with the ultimate aim of creating not only an effective and safe contraceptive method, but also a drug able to meet the need for treatment of other conditions, such as acne, seborrhea, and hirsutism, with few or no side effects. With this objective, a new progestin, chlormadinone acetate (CMA), has been developed as a derivative of progesterone for ­contraception. This new molecule has been introduced in combination with ethinylestradiol (EE) 30 µg as a safe ­contraceptive with antiandrogenic properties. Many clinical studies have investigated this new oral combination and found it to be safe, with a Pearl Index similar to that of other combined hormonal contraceptives. CMA, because of its antiandrogenic properties, has been also considered effective for resolution of acne, seborrhea, and hirsutism. The data show it to be a safe molecule in terms of glucose and lipid metabolism. No major weight changes have been linked with its use, and it seems to be the only progestin able to reduce fat mass during use. The CMA-EE combination is well tolerated and acceptable to women. Adverse events related to its use are similar to those reported with other third-generation ­contraceptives. We can conclude that CMA-EE is an effective, safe, and well tolerated ­antiandrogenic hormonal contraceptive.Keywords: chlormadinone acetate, acne, weight, metabolism, safety, hormonal contraceptive http://www.dovepress.com/efficacy-safety-and-patient-acceptability-of-the-combined-chlormadinon-a5199
collection DOAJ
language English
format Article
sources DOAJ
author Serena Ferrari
Marianna Cannoletta, Matteo Generali
et al.
spellingShingle Serena Ferrari
Marianna Cannoletta, Matteo Generali
et al.
Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive
Open Access Journal of Contraception
author_facet Serena Ferrari
Marianna Cannoletta, Matteo Generali
et al.
author_sort Serena Ferrari
title Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive
title_short Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive
title_full Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive
title_fullStr Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive
title_full_unstemmed Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive
title_sort efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive
publisher Dove Medical Press
series Open Access Journal of Contraception
issn 1179-1527
publishDate 2010-09-01
description Serena Ferrari, Marianna Cannoletta, Matteo Generali, Lucia Cazzato, Angelo CagnacciDepartment of Obstetrics, Gynecology, and Pediatrics, Azienda Ospedaliero, Universitaria di Modena, ItalyAbstract: Since their introduction in 1959, development of hormonal contraceptives has been ongoing, with the ultimate aim of creating not only an effective and safe contraceptive method, but also a drug able to meet the need for treatment of other conditions, such as acne, seborrhea, and hirsutism, with few or no side effects. With this objective, a new progestin, chlormadinone acetate (CMA), has been developed as a derivative of progesterone for ­contraception. This new molecule has been introduced in combination with ethinylestradiol (EE) 30 µg as a safe ­contraceptive with antiandrogenic properties. Many clinical studies have investigated this new oral combination and found it to be safe, with a Pearl Index similar to that of other combined hormonal contraceptives. CMA, because of its antiandrogenic properties, has been also considered effective for resolution of acne, seborrhea, and hirsutism. The data show it to be a safe molecule in terms of glucose and lipid metabolism. No major weight changes have been linked with its use, and it seems to be the only progestin able to reduce fat mass during use. The CMA-EE combination is well tolerated and acceptable to women. Adverse events related to its use are similar to those reported with other third-generation ­contraceptives. We can conclude that CMA-EE is an effective, safe, and well tolerated ­antiandrogenic hormonal contraceptive.Keywords: chlormadinone acetate, acne, weight, metabolism, safety, hormonal contraceptive
url http://www.dovepress.com/efficacy-safety-and-patient-acceptability-of-the-combined-chlormadinon-a5199
work_keys_str_mv AT serenaferrari efficacysafetyandpatientacceptabilityofthecombinedchlormadinoneacetateethinylestradioloralcontraceptive
AT mariannacannolettaampnbspmatteogenerali efficacysafetyandpatientacceptabilityofthecombinedchlormadinoneacetateethinylestradioloralcontraceptive
AT etal efficacysafetyandpatientacceptabilityofthecombinedchlormadinoneacetateethinylestradioloralcontraceptive
_version_ 1725569838604091392